Search for:
Search for:
Healthcare Professionals
Publications
Contact
News
Español
Magazine
Radio
*
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Donate
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Supporter Program
Awareness Campaigns
Host an Event
Events
MS Focus on Fashion
The inaugural MS Focus on Fashion, will take place on Nov. 6, in Dania Beach, Fla.
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Healthcare Advisory Board
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
Computer Program
The MS Focus Computer Program provides laptop or desktop computers for individuals with MS on...
/Get-Help/MSF-Programs-Grants/Computer-Program
Shop
Privacy
Terms of Use
Site Map
PET scans reveal ‘smoldering’ inflammation in patients with MS
April 25, 2024
A new study suggests positron emission tomography brain scans could reveal hidden inflammation in patients with multiple sclerosis who are being treated with highly-effective treatments. The new technique could lead to more advanced MS treatments.
The study started when researchers at Brigham Multiple Sclerosis Center and the Ann Romney Center noticed patients who were being treated with the most effective MS treatments available were experiencing worsening symptoms. The team has worked for the past eight years on developing an approach of imaging cells called microglia. Microglia are immune cells in the brain that are thought to have a role in MS disease progression but cannot be seen by a routine MRI. The team developed a technique called F18 PBR 06 PET imaging. It involves the injection of a tracer, or dye, which binds to the microglia cells. According to the researchers, increased microglial activity means more atrophy of gray matter in the brain.
In their paper, the authors describe the term “smoldering” inflammation. Just as a smoldering fire can burn slowly without smoke or flame, smoldering inflammation may linger in patients with MS, driving disease progression and symptoms, even when it cannot be assessed on MRI.
The newly published study involved performing PET scans on 22 people with MS and eight healthy controls. Researchers measured the glial activity load on the PET scans, a new measure where lab members looked at the level of smoldering inflammation from microglia in MS patients. They compared those scans to patients’ disability and fatigue levels and not only found that PET scans could show hidden inflammation caused by microglia, but the damage to patients’ brains correlated with the disability and fatigue levels they were experiencing. The researchers were also able to better classify patients with MS between high-efficacy and low-efficacy treatments. Those being treated with low-efficacy treatments had more abnormalities on their PET scans, suggesting more microglial cell activation. Those using high-efficacy treatments had a lower degree of PET abnormality than those on no or low efficacy treatments, but still had an abnormal increase of microglial activation compared to healthy people, suggesting that while high-efficacy treatments helped to reduce neuroinflammation, there was residual inflammation despite treatment, which could account for future worsening and progression independent of relapse activity in these MS patients.
One limitation to the study is the initial group was small. The authors note that PET scans can also be expensive and expose patients to some level of radiation, whereas MRIs do not. The authors said that radiation could potentially be reduced because of the long half-life and the requirement for a lower administered dose of the F18 PBR06 tracer being used. The tracer also produces better imaging characteristics compared to previously used tracers with shorter half-lives.
The researchers said despite the limitations, the study shines an important light on the power of PET scanning, specifically for the purposes of finding microglial activation. They said before the technique can be used routinely in a clinical setting, it must be validated on a larger sample size. Other longer half-life PET tracers have been approved by the FDA for clinical use, for example, amyloid PET tracers for studying Alzheimer’s disease. If approved, F-18 PBR06 could also be used as a tool to personalize and predict a patient’s treatment course in MS and other brain diseases. However, the authors note that even prior to approval, F-18 PBR06 can be used to help advance drug development and perform multicentric clinical trials.
The findings were published in
Clinical Nuclear Medicine
.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more